Correction: COVID-19 Vaccine Updates for VFC Providers

Wisconsin Department of Health Services sent this bulletin at 09/12/2025 01:23 PM CDT
Wisconsin Department of Health Services

Wisconsin Vaccines for Children Program (VFC)

Correction: COVID-19 Vaccine Updates for VFC Providers

This message is being sent to VFC providers, local health officers, Tribal health directors, local health department staff, local health department nurses and select DHS staff. 

Correction: There was a formatting error in the previous message about the formulations for mNEXSPIKE and NUVAXOVID. There are four COVID-19 vaccines available for the 2025-26 season. COMIRNATY, SPIKEVAX, mNEXSPIKE, and NUVAXOVID. The correct formulations and doses are listed below.

As a reminder, at this time 2025-26 COVID-19 vaccines are not available through the VFC program. Availability is dependent on an ACIP recommendation and resolution to include in the VFC program. The ACIP meeting is currently scheduled for September 18–19, 2025. The immunization program will notify providers if and when COVID vaccine information changes.

Commercially available 2025–26 COVID-19 vaccines

COMIRNATY:

  • 10 mcg formulation for use in individuals 5 years through 11 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
  • 30 mcg formulation for use in individuals who are 65 years of age and older, or 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

SPIKEVAX:

  • 0.25 mL formulation for individuals 6 months through 11 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.
  • 0.5 mL formulation for individuals who are 65 years of age and older, or 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

mNEXSPIKE:

  • 0.2 mL formulation for individuals who are 65 years of age and older, or 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

NUVAXOVID:

  • 0.5 mL formulation for individuals who are 65 years of age and older, or 12 years through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.